Published in Cancer Weekly, May 27th, 2003
"Imatinib (Glivec, formerly known as STI571) effectively blocks the ATP-binding site of the bcr/abl fusion protein thereby inactivating selectively the tyrosine kinase activity of bcr/abl," researchers in Germany report.
"Therefore, it is a promising drug in Philadelphia chromosome-positive chronic myeloid leukemia showing high hematologic and cytogenetic response rates combined with a mild toxicity profile," wrote G. Baskaynak and colleagues, Humboldt University.
The researchers concluded: "Here we report two cases of squamous cell carcinoma of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly